These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24708143)

  • 1. Dedicated bifurcation paclitaxel-eluting stent BiOSS Expert® in the treatment of distal left main stem stenosis.
    Bil J; Gil RJ; Vassilev D; Rzezak J; Kulawik T; Pawlowski T
    J Interv Cardiol; 2014 Jun; 27(3):242-51. PubMed ID: 24708143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIM® dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry.
    Gil RJ; Bil J; Grundeken MJ; Iñigo Garcia LA; Vassilev D; Kern A; Pawłowski T; Wykrzykowska JJ; Serruys PW
    EuroIntervention; 2016 Nov; 12(10):1246-1254. PubMed ID: 26465375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial.
    Gil RJ; Bil J; Džavík V; Vassilev D; Kern A; Formuszewicz R; Zalewska-Adamiec M; Dobrzycki S
    Can J Cardiol; 2015 May; 31(5):671-8. PubMed ID: 25828372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-man study of dedicated bifurcation sirolimus-eluting stent: 12-month results of BiOSS LIM® Registry.
    Gil RJ; Bil J; Vassiliev D; Iñigo Garcia LA
    J Interv Cardiol; 2015 Feb; 28(1):51-60. PubMed ID: 25689548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-man study of paclitaxel-eluting stent BiOSS (Bifurcation Optimisation Stent System) dedicated for coronary bifurcation stenoses: three months results.
    Gil RJ; Vassiliev D; Michałek A; Kern A; Formuszewicz R; Dobrzycki S; Lesiak M; Wójcik J; Kardaszewicz P; Lekston A
    Kardiol Pol; 2012; 70(1):45-52. PubMed ID: 22267425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-man study of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C® - three-month results.
    Gil RJ; Bil J; Kern A; Pawłowski T
    Kardiol Pol; 2018; 76(2):464-470. PubMed ID: 29192951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dedicated bifurcation stents or regular drug eluting stents in distal left main stenosis: A retrospective study.
    Kern A; Gil RJ; Bojko K; Rzeszowski B; Bednarski K; Górny J; Bil J
    Cardiol J; 2018; 25(2):188-195. PubMed ID: 28714525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dedicated paclitaxel-eluting bifurcation stent BiOSS® (bifurcation optimisation stent system): 12-month results from a prospective registry of consecutive all-comers population.
    Gil RJ; Vassilev D; Michalek A; Kern A; Formuszewicz R; Dobrzycki S; Wójcik J; Lesiak M; Kardaszewicz P; Lekston A
    EuroIntervention; 2012 Jul; 8(3):316-24. PubMed ID: 22829507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: Pooled analysis from two randomized studies.
    Gil RJ; Bil J; Kern A; Iñigo Garcia LA; Formuszewicz R; Dobrzycki S; Vassilev D; Segiet A
    Cardiol J; 2018; 25(3):308-316. PubMed ID: 28840591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and angiographic results of angioplasty with a paclitaxel-eluting stent for unprotected left main coronary artery disease (a study of 101 consecutive patients).
    Cherradi R; Ouldzein H; Zouaoui W; Elbaz M; Puel J; Carrié D
    Arch Cardiovasc Dis; 2008 Jan; 101(1):11-7. PubMed ID: 18391867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 12-month intravascular ultrasound observations from BiOSS® first-in-man studies.
    Gil RJ; Bil J; Costa RA; Gil KE; Vassiliev D
    Int J Cardiovasc Imaging; 2016 Sep; 32(9):1339-1347. PubMed ID: 27314841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM® stent: the randomised, multicentre, open-label, controlled POLBOS II trial.
    Gil RJ; Bil J; Grundeken MJ; Kern A; Iñigo Garcia LA; Vassilev D; Pawłowski T; Formuszewicz R; Dobrzycki S; Wykrzykowska JJ; Serruys PW
    EuroIntervention; 2016 Dec; 12(11):e1404-e1412. PubMed ID: 26600564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiographic study of the clinical liaison of drug-eluting stent and paclitaxel-eluting balloon in unifocal side branch ostium stenosis (ASCLEPIUS).
    Jim MH; Wu EB; Chan CY; Wong KL; Fung RC; Yiu KH
    Heart Vessels; 2017 Sep; 32(9):1045-1050. PubMed ID: 28357514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies.
    Gil RJ; Bil J; Kern A; Iñigo-Garcia LA; Formuszewicz R; Dobrzycki S; Vassilev D; Mehran R
    Cardiovasc Ther; 2020; 2020():6760205. PubMed ID: 32411301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.
    Stella PR; Belkacemi A; Dubois C; Nathoe H; Dens J; Naber C; Adriaenssens T; van Belle E; Doevendans P; Agostoni P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1138-46. PubMed ID: 22422607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of a dedicated bifurcation stent versus provisional stenting in the treatment of coronary bifurcation lesions.
    Généreux P; Kumsars I; Lesiak M; Kini A; Fontos G; Slagboom T; Ungi I; Metzger DC; Wykrzykowska JJ; Stella PR; Bartorelli AL; Fearon WF; Lefèvre T; Feldman RL; LaSalle L; Francese DP; Onuma Y; Grundeken MJ; Garcia-Garcia HM; Laak LL; Cutlip DE; Kaplan AV; Serruys PW; Leon MB
    J Am Coll Cardiol; 2015 Feb; 65(6):533-43. PubMed ID: 25677311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: a randomized trial.
    Liistro F; Porto I; Angioli P; Grotti S; Ducci K; Falsini G; Bolognese L
    Am Heart J; 2013 Nov; 166(5):920-6. PubMed ID: 24176449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of distal/bifurcation left main restenosis after drug eluting stents implantation: single center experience.
    Rigatelli G; Cardaioli P; Dell'Avvocata F; Giordan M; Vassilev D; Fraccaro C; Roncon L; Faggian G
    Cardiovasc Revasc Med; 2014 Mar; 15(2):76-9. PubMed ID: 24560299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
    Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
    J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.